ADDED
As of February 27, 2026, 41,119,820 of the Registrant s ordinary shares, par value $0.0001 per share, were outstanding.
Our first-in-class lead asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients.
Plinabulin has been administered to over 700 cancer patients with generally good tolerability and is being developed as a potential pipeline in a drug in various cancer indications as a direct anti-cancer agent with safety benefit of reducing chemotherapy-induced neutropenia (CIN).
After a successful phase 3 study (DUBLIN-3) in NSCLC, Plinabulin regimen is in a confirmatory global phase 3 study in second- and third-line NSCLC with epidermal growth factor receptor (EGFR) wild type after progression on prior immune checkpoint inhibitors, a severe unmet medical need.
SEED has advanced its wholly owned lead oncology asset, a novel RBM39 degrader into phase 1 clinical studies in January 2026.
Plinabulin is a differentiated microtubule modulator with different binding and kinetics from other microtubule stabilizing or depolymerizing agents.
By depolymerizing microtubule, it activates the immune defense protein GEF-H1, which leads to induction of innate and adaptive immunity via dendritic cell (DC) maturation.
In June 2025, we published in Cell Press Med Plinabulin s DC maturation benefit to responding patients in eight cancers, based on our multi-year collaboration with The University of Texas MD Anderson Cancer Center, or MD Anderson.
Steinmetz group published in Cell on the structural basis of microtubule-mediated signal transduction, which suggests the important role of microtubule as signal sensors to regulate cellular function, further supporting Plinabulin s unique biological function.
With this unique immune mechanism, Plinabulin is being studied as an anti-cancer agent in a number of company-sponsored studies and investigator-initiated studies in late-line and first-line cancer treatments, including targeting patients progressed on checkpoint inhibitors in NSCLC with EGFR wild type, which we believe presents a severe unmet medical need.
REMOVED
As of February 28, 2025, 40,316,320 of the Registrant s ordinary shares, par value $0.0001 per share, were outstanding.
Our first-in-class lead asset, Plinabulin, which has been administered to over 700 cancer patients with generally good tolerability, is being developed as a potential pipeline in a drug in various cancer indications as a direct anti-cancer agent.
Plinabulin binds in a unique pocket in tubulin which is different from other tubulin binders such as taxane, vinca, and colchicine, and releases an immune defense protein GEF-H1, which produces the potent effect of maturing immune dendritic cells, leading to T-cell activation for a potential durable anti-cancer benefit.
Therefore, we believe Plinabulin s mechanism stimulates both innate and adaptive immunity.
We are applying these insights to our current clinical studies to target mechanism-based patient populations.
Plinabulin s unique binding site has also led to clinical findings that have repeatedly shown significant reductions in CIN, which may provide added clinical and safety benefits to cancer patients.
Plinabulin is being studied as an anti-cancer agent in a number of company-sponsored studies and investigator-initiated studies.
We completed a randomized global Phase 3 study of Plinabulin in combination with docetaxel compared with docetaxel alone for second- and third- line treatment of NSCLC, epidermal growth factor receptor, or EGFR, wild type (DUBLIN-3 Phase 3 registration study).
The DUBLIN-3 study enrolled 559 patients at 58 clinical sites globally and the final results from the study showed that the Plinabulin and docetaxel combination had statistically significant and clinically meaningful overall survival benefit compared to standard of care docetaxel alone.
Key secondary endpoints were also achieved with additional clinically significant benefits in progression free survival (PFS) and objective response rate (ORR), coupled with a significant reduction in grade 4 neutropenia, with over 80% reduction.